<DOC>
	<DOC>NCT00297180</DOC>
	<brief_summary>GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.</brief_summary>
	<brief_title>Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Inclusion criteria: Have a BMI within range 30.0 to 40.0kg/m2, inclusive. Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or postmenopausal per protocol definition). Exclusion criteria: History of eating disorders. Recent history of weight loss or gain. Had gastrointestinal surgery for treatment of obesity. Type 1 or type 2 diabetes mellitus. Have a positive urine drug screen. Have liver disease. Have hepatitis B, hepatitis C, or HIV antibodies. Have a thyroid disorder that is not under control with medication. Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or cancer). Are unable to participate in an exercise program. Have used weight loss drugs within 3 months before the start of the study. Are currently using warfarin, digoxin, oral anticoagulants (other than aspirin and nonsteroidal antiinflammatory drugs), oral or injectable corticosteroids (inhaled &amp; intranasal corticosteroids are permitted), or antiretroviral medications. Used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication. High or low blood pressure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hunger</keyword>
	<keyword>obesity</keyword>
	<keyword>sodium-dependent glucose transporter</keyword>
	<keyword>GW869682</keyword>
	<keyword>body composition</keyword>
	<keyword>SGLT2 inhibitor</keyword>
	<keyword>weight loss</keyword>
</DOC>